Rani Therapeutics Holdings, Inc. (RANI): Nasdaq/NYSE listing notice — Rani Therapeutics Q1 net loss narrows to $8M; Nasdaq bid price non-compliance; CFO to depart

Rani Therapeutics Holdings, Inc.

Q1 net loss $8.0M, narrowed from $12.7M YoY; cash $43.4M expected to fund operations into Q4 2027.
Received Nasdaq deficiency notice for bid price below $1.00; 180-day cure period until Nov 9, 2026.
CFO Svai Sanford to resign after successor appointed; separation includes 9 months salary ($491,400) and accelerated vesting.
Phase 1 study of oral GLP-1/GLP-2 dual agonist RT-114 ongoing in obesity; partnered with ProGen.
Appointed new CTO, Head of Strategy, and Strategic Advisor in Q1 2026.

item 2.02 item 3.01 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Svai Sanford

Chief Financial Officer

RANI · Rani Therapeutics Holdings, Inc.

Filed: May 15, 2026, 4:08 PM ET

On May 12, 2026, Svai Sanford, the Company’s Chief Financial Officer, advised the Company that he will resign from his position following the appointment of his successor.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Rani Therapeutics Holdings, Inc. reported the first quarter ended March 31, 2026 results: revenue $1.7 million, net income $8.0 million.

Period: the first quarter ended March 31, 2026
Revenue: $1.7 million
Net income: $8.0 million
Result: reported results

Exact text from the filing

and license agreement with Chugai, to be sufficient to fund its operations into the fourth quarter of 2027. • Contract revenue for the three months ended March 31, 2026 were $1.7 million, compared to $0.2 million for the same period in 2025. The increase of $1.5 million was primarily attributable to the collaboration and license agreement with Chugai. • Research

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Rani Therapeutics Holdings, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1), 5810(c)(3)(A)

Exact text from the filing

May 11, 2026, the Company received a letter from the Nasdaq Stock Exchange LLC (“Nasdaq”), notifying the Company that, based on the closing bid price of the Company’s Class A common stock, par value $0.0001 per share (th

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Svai Sanford departed as Chief Financial Officer at Rani Therapeutics Holdings, Inc..

Action: resign
Role: Chief Financial Officer

Exact text from the filing

On May 12, 2026, Svai Sanford, the Company’s Chief Financial Officer, advised the Company that he will resign from his position following the appointment of his successor.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Rani Therapeutics Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-226691

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.